Jeonjinbio Co., Ltd. (KOSDAQ:110020)

Jeonjinbio Statistics

Total Valuation

Jeonjinbio has a market cap or net worth of KRW 20.61 billion. The enterprise value is 14.92 billion.

Market Cap	20.61B
Enterprise Value	14.92B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Jeonjinbio has 9.06 million shares outstanding. The number of shares has increased by 10.60% in one year.

Current Share Class	9.06M
Shares Outstanding	9.06M
Shares Change (YoY)	+10.60%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.84%
Owned by Institutions (%)	n/a
Float	7.94M

Valuation Ratios

The trailing PE ratio is 28.32.

PE Ratio	28.32
Forward PE	n/a
PS Ratio	1.41
PB Ratio	1.16
P/TBV Ratio	1.16
P/FCF Ratio	n/a
P/OCF Ratio	40.84
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.97, with an EV/FCF ratio of -42.04.

EV / Earnings	20.49
EV / Sales	1.02
EV / EBITDA	15.97
EV / EBIT	50.51
EV / FCF	-42.04

Financial Position

The company has a current ratio of 8.77

Current Ratio	8.77
Quick Ratio	7.51
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	84.06

Financial Efficiency

Return on equity (ROE) is 4.14% and return on invested capital (ROIC) is 2.46%.

Return on Equity (ROE)	4.14%
Return on Assets (ROA)	0.95%
Return on Invested Capital (ROIC)	2.46%
Return on Capital Employed (ROCE)	1.65%
Weighted Average Cost of Capital (WACC)	1.23%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.76
Inventory Turnover	7.29

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.91% in the last 52 weeks. The beta is -0.55, so Jeonjinbio's price volatility has been lower than the market average.

Beta (5Y)	-0.55
52-Week Price Change	-8.91%
50-Day Moving Average	2,543.80
200-Day Moving Average	2,965.45
Relative Strength Index (RSI)	40.39
Average Volume (20 Days)	62,772

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Jeonjinbio had revenue of KRW 14.65 billion and earned 728.22 million in profits. Earnings per share was 80.34.

Revenue	14.65B
Gross Profit	4.06B
Operating Income	295.48M
Pretax Income	728.22M
Net Income	728.22M
EBITDA	934.70M
EBIT	295.48M
Earnings Per Share (EPS)	80.34

Balance Sheet

The company has 5.68 billion in cash and n/a in debt, with a net cash position of 5.68 billion or 627.49 per share.

Cash & Cash Equivalents	5.68B
Total Debt	n/a
Net Cash	5.68B
Net Cash Per Share	627.49
Equity (Book Value)	17.72B
Book Value Per Share	1,956.58
Working Capital	8.70B

Cash Flow

In the last 12 months, operating cash flow was 504.61 million and capital expenditures -859.63 million, giving a free cash flow of -355.01 million.

Operating Cash Flow	504.61M
Capital Expenditures	-859.63M
Free Cash Flow	-355.01M
FCF Per Share	-39.19

Margins

Gross margin is 27.68%, with operating and profit margins of 2.02% and 4.97%.

Gross Margin	27.68%
Operating Margin	2.02%
Pretax Margin	4.97%
Profit Margin	4.97%
EBITDA Margin	6.38%
EBIT Margin	2.02%
FCF Margin	n/a

Dividends & Yields

Jeonjinbio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.60%
Shareholder Yield	-10.60%
Earnings Yield	3.53%
FCF Yield	-1.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Jeonjinbio has an Altman Z-Score of 11.44 and a Piotroski F-Score of 4.

Altman Z-Score	11.44
Piotroski F-Score	4